देश: आयरलैंड
भाषा: अंग्रेज़ी
स्रोत: HPRA (Health Products Regulatory Authority)
LEUPRORELIN ACETATE
Takeda UK Limited
L02AE02
LEUPRORELIN ACETATE
30 Milligram
Unknown
Product subject to prescription which may not be renewed (A)
Gonadotropin releasing hormone analogues
Transfer Pending
2011-04-08
Prostap 6 DCS IE 1 PACKAGE LEAFLET: INFORMATION FOR THE USER PROSTAP ® 6 DCS 30 mg Powder and Solvent for Prolonged-release Suspension for Injection in Pre-filled Syringe Leuprorelin acetate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What PROSTAP 6 is and what it is used for 2. What you need to know before you take PROSTAP 6 3. How to take PROSTAP 6 4. Possible side effects 5. How to store PROSTAP 6 6. Contents of the pack and other information 1. WHAT PROSTAP 6 IS AND WHAT IT IS USED FOR PROSTAP 6 is a synthetic hormone, which can be used to reduce levels of testosterone circulating in the body. PROSTAP 6 is used to treat prostate cancer in men. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PROSTAP 6 PROSTAP 6 is not recommended for use in children under the age of 18 years. DO NOT TAKE PROSTAP 6: • If you are allergic (hypersensitive) to leuprorelin acetate (PROSTAP 6, PROSTAP SR or PROSTAP 3) or any of the other ingredients of PROSTAP 6 (listed in section 6). • If you are a man with prostate cancer, and have had injections of a synthetic hormone in the past that has not worked, or you have had an operation to remove your testicles. पूरा दस्तावेज़ पढ़ें
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT PROSTAP 6 DCS 30 mg Powder and Solvent for Prolonged-release Suspension for Injection in Pre-filled Syringe 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Powder: contains 30 mg leuprorelin acetate. Solvent: Solvent contains approximately 0.4mg (<1mmol) sodium (as carmellose sodium). When reconstituted with sterile solvent, the suspension contains 30 mg leuprorelin acetate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for prolonged-release suspension for injection in pre-filled syringe (Dual Chamber Syringe). Powder: A sterile, lyophilised, white, odourless powder. Solvent: A clear odourless, slightly viscous, sterile solvent. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS (i) Metastatic prostate cancer (ii) Locally advanced prostate cancer, as an alternative to surgical castration (iii) As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer (iv) As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression (See Section 5.1) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Prostate Cancer: The usual recommended dose is 30 mg presented as a six month depot injection and administered as a single subcutaneous injection at intervals of six months. The majority of patients will respond to this dosage. PROSTAP 6 therapy should not be discontinued when remission or improvement occurs. As with other drugs administered regularly by injection, the injection site should be varied periodically. Response to PROSTAP 6 therapy should be monitored by clinical parameters and by measuring prostate-specific antigen (PSA) serum levels. Clinical studies with leuprorelin पूरा दस्तावेज़ पढ़ें